Clinical and Preclinical Studies with Low-Clearance Liposomal Amikacin (MiKasome®)
The introduction of aminoglycoside antibiotics in the mid-twentieth century led to dramatic changes in the treatment of tuberculosis followed by improved therapy of the emerging problem of Gram-negative bacterial infections. Clinical experience soon revealed that although the aminoglycosides possess a wide spectrum of antimicrobial activity, they may also produce serious, dose-related damage to the kidneys and the auditory/vestibular apparatus. As a result, aminoglycosides require therapeutic drug monitoring to maintain their plasma concentrations within a narrow therapeutic window, and aminoglycosides are now often reserved for the most severe infections despite their excellent antimicrobial properties.
KeywordsKlebsiella Pneumoniae Urinary Recovery Mononuclear Phagocyte System Multilamellar Liposome Plasma Ultrafiltrate
Unable to display preview. Download preview PDF.
- 2.Fielding RM, Feistner B, Moon-McDermott L et al. Liposomal amikacin (MiKasome) prolongs plasma and tissue residence and reduces urinary excretion of amikacin in rats. American Society for Microbiology, 97th General Meeting, Miami Beach, May 4–8, 1997.Google Scholar
- 3.Fielding RM, Feistner B, Moon-McDermott L et al. Liposomal amikacin (MiKasome®): reduced clearance and volume of distribution in rats. Pharm Res 1996; 13: 478–479.Google Scholar
- 4.Baggot JD, Ling GV, Chatfield RC. Clinical pharmacokinetics of amikcain in dogs. Am J Vet Res 1985; 461793–6.Google Scholar
- 5.Fabrey R, Olson J, Adler-Moore J. Differences in in vitro antimicrobial activity of amikacin (Ami) following its encapsulation in stable liposomes (MiKasome). American Society for Microbiology, 97th General Meeting, Miami Beach, May 4–8, 1997.Google Scholar
- 6.Eng E, Satorius A, Proffitt RT, Adler-Moore JP. Prophylaxis of Klebsiella pneumonia sepsis by MiKasome (MK), a liposomal formulation of amikacin (AK). American Society for Microbiology, 96th General Meeting, New Orleans, May 19–23, 1996.Google Scholar
- 7.Eng ET. Prophylactic and therapeutic treatment of gram negative septicemia with liposomal and non-liposomal encapsulated amikacin in immunocompromized mice. Thesis presented to California State Polytechnic University, Pomona, CA, 1996.Google Scholar
- 8.Eng E, McAndrews B, Satorius A et al. Comparative efficacy of amikacin (Ami) and liposomal amikacin (MiKasome) in the treatment of Klebsiella pneumoniae infection in mice. American Society for Microbiology, 97th General Meeting, Miami Beach, May 4–8, 1997.Google Scholar
- 9.Xiong Y-Q, Adler-Moore J, Zack P, Bayer AS. Efficacy of MiKasome (a liposomal amikacin formulation) vs free amikacin in experimental endocarditis due to Pseudomonas aeruginosa. American Society for Microbiology, 97th General Meeting, Miami Beach, May 4–8, 1997.Google Scholar
- 11.Zack PM, Fielding RM. Unpublished data.Google Scholar
- 12.Fielding RM, Mukwaya GM, Washington C et al. A multiple dose phase 1 safety and pharmacokinetic study of low-clearance liposomal Amikacin (MiKasome) in HIV serpositive patients. Infectious Diseases Society of America, 35th Annual Meeting, San Francisco, September 15, 1997.Google Scholar
- 13.Benet LZ et al. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG et al, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1714.Google Scholar